Compare BLKB & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | FOLD |
|---|---|---|
| Founded | 1981 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | 2004 | 2007 |
| Metric | BLKB | FOLD |
|---|---|---|
| Price | $62.00 | $10.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $70.50 | $30.29 |
| AVG Volume (30 Days) | 353.7K | ★ 4.6M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,136,093,000.00 | $598,704,000.00 |
| Revenue This Year | N/A | $21.49 |
| Revenue Next Year | $4.09 | $18.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.28 |
| 52 Week Low | $54.56 | $5.51 |
| 52 Week High | $81.63 | $11.00 |
| Indicator | BLKB | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 78.23 |
| Support Level | $60.62 | $9.73 |
| Resistance Level | $63.59 | $10.05 |
| Average True Range (ATR) | 1.89 | 0.36 |
| MACD | 0.55 | 0.04 |
| Stochastic Oscillator | 70.50 | 82.59 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.